|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of the transcription factor cAMP response element modulator (CREM) α promotes altered cytokine expression in SLE.
|
31653682 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The transcriptional factor, inducible cAMP early repressor/cAMP response element modulator (ICER/CREM), has been shown to be induced in Th17 cells and to be overexpressed in CD4<sup>+</sup> T cells from the patients with systemic lupus erythematosus (SLE).
|
30150402 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we propose that CREMα is essential for the expansion of double negative T cells in SLE.
|
24297179 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that the transcription factor cAMP-responsive element modulator α (CREMα), which is expressed at increased levels in T cells from systemic lupus erythematosus patients, contributes to transcriptional silencing of CD8A and CD8B.
|
24047902 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This review summarizes the most recent findings on CREM protein expression in various cell types, in particular its effects on T lymphocyte biology in the context of both health and SLE.
|
23491535 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous data from our group identified cAMP-responsive element modulator α (CREMα), which is up-regulated in SLE T cells, as a key regulator of epigenetic patterns and gene transcription, e.g. that of IL2 and IL17 genes.
|
23124208 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
cAMP response element modulator α controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus.
|
23019580 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The activity of calcium/calmodulin-dependent protein kinase IV (CaMK4) is increased in T cells from patients with systemic lupus erythematosus (SLE) and has been shown to reduce IL-2 production by promoting the effect of the transcriptional repressor cAMP responsive element modulator-α on the IL2 promoter.
|
22942433 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings extend the understanding of CREM gene regulation in the context of T cell activation and disclose another difference in the transcriptional machinery in SLE T cells.
|
21757709 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the first time, we provide direct evidence that CREMα mediates silencing of the IL2 gene in SLE T cells though histone deacetylation and CpG-DNA methylation.
|
21976679 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate an extended role for CREMα in the immunopathogenesis of SLE because it contributes to increased expression of IL-17A.
|
22025620 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
More importantly, CREM promoter activity mirrors reliably disease activity in SLE patients, underscoring its potential role as a biomarker for the prediction of flares in SLE patients.
|
21097497 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The cAMP response element modulator (CREM)alpha is a widely expressed transcriptional repressor that is important for the termination of the T cell immune response and contributes to the abnormal T cell function in patients with systemic lupus erythematosus.
|
19299714 |
2009 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The discovery of specific non-toxic medications that block the expression of CREM-alpha may prove useful in reversing the aberrant T cell function in SLE.
|
17211988 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The discovery of specific non-toxic medications that block the expression of CREM-alpha may prove useful in reversing the aberrant T cell function in SLE.
|
17211988 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study identifies CaMKIV as being responsible for the increased expression of CREM and the decreased production of IL-2 in SLE T cells and demonstrates that anti-TCR/CD3 antibodies present in SLE sera can account for the increased expression of CREM and the suppression of IL-2 production.
|
15841182 |
2005 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This study identifies CaMKIV as being responsible for the increased expression of CREM and the decreased production of IL-2 in SLE T cells and demonstrates that anti-TCR/CD3 antibodies present in SLE sera can account for the increased expression of CREM and the suppression of IL-2 production.
|
15841182 |
2005 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This article will review the defective transcription regulation of IL-2 in SLE T cells, which is the result of decreased expression of the enhancers NF-kappa B and AP1 and the increased expression of the transcriptional repressor CREM.
|
15204092 |
2005 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
T cells from patients with systemic lupus erythematosus express increased levels of the cAMP response element modulator (CREM) that has been shown to bind to the IL-2 promoter and suppress its activity.
|
15322221 |
2004 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of the expression of CREM mRNA and protein by an antisense CREM plasmid, which was force expressed in SLE T cells by electroporation, resulted in decreased CREM protein binding to the IL-2 promoter and increased expression of IL-2 mRNA and protein.
|
12370343 |
2002 |